Here’s how analysts see Mallinckrodt PLC (NYSE:MNK) after this past week.

November 23, 2017 - By Vivian Park

 Here's how analysts see Mallinckrodt PLC (NYSE:MNK) after this past week.
Investors sentiment decreased to 0.72 in 2017 Q2. Its down 0.30, from 1.02 in 2017Q1. It is negative, as 49 investors sold Mallinckrodt PLC shares while 136 reduced holdings. 37 funds opened positions while 96 raised stakes. 95.02 million shares or 0.42% more from 94.62 million shares in 2017Q1 were reported.
National Planning, a California-based fund reported 87,761 shares. Pggm Investments holds 0.02% of its portfolio in Mallinckrodt PLC (NYSE:MNK) for 70,642 shares. Hartford reported 29,007 shares. Omers Administration owns 5,800 shares. Stifel Finance Corporation owns 27,805 shares for 0% of their portfolio. 8,406 were reported by Sumitomo Mitsui Asset. Ameriprise Financial invested in 0.04% or 1.94 million shares. 2.16 million are held by Dimensional Fund Ltd Partnership. West Oak Capital Ltd stated it has 92 shares. Moreover, Paradigm Capital Mgmt Incorporated Ny has 0.12% invested in Mallinckrodt PLC (NYSE:MNK). Retail Bank Of America De reported 264,544 shares. Neuberger Berman Grp Limited Company accumulated 0% or 51,593 shares. Boston Ptnrs stated it has 0% in Mallinckrodt PLC (NYSE:MNK). Broadwood Cap holds 322,411 shares or 2.66% of its portfolio. Profund Advisors Limited Liability reported 5,971 shares or 0.01% of all its holdings.

Since June 2, 2017, it had 7 insider buys, and 0 insider sales for $521,684 activity. Shares for $40,237 were bought by O’Neill Hugh M. on Thursday, June 8. The insider Trudeau Mark bought 1,000 shares worth $40,174. On Friday, June 9 the insider LLOYD RONALD K. bought $206,320. $39,881 worth of stock was bought by Romano Steven J. on Friday, June 9.

Mallinckrodt PLC (NYSE:MNK) Ratings Coverage

Among 21 analysts covering Mallinckrodt (NYSE:MNK), 9 have Buy rating, 0 Sell and 12 Hold. Therefore 43% are positive. Mallinckrodt had 86 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Mallinckrodt PLC (NYSE:MNK) has “Neutral” rating given on Tuesday, September 29 by Nomura. The firm has “Buy” rating given on Friday, August 4 by Stifel Nicolaus. The stock of Mallinckrodt PLC (NYSE:MNK) has “Neutral” rating given on Wednesday, November 8 by Goldman Sachs. As per Wednesday, September 13, the company rating was downgraded by Mizuho. Mizuho maintained it with “Buy” rating and $69 target in Friday, February 3 report. On Friday, August 12 the stock rating was initiated by Stifel Nicolaus with “Buy”. On Friday, February 19 the stock rating was initiated by Wells Fargo with “Outperform”. On Tuesday, November 21 the stock rating was downgraded by Oppenheimer to “Hold”. The company was maintained on Wednesday, August 31 by Deutsche Bank. Cantor Fitzgerald initiated Mallinckrodt PLC (NYSE:MNK) on Friday, June 16 with “Overweight” rating. Below is a list of Mallinckrodt PLC (NYSE:MNK) latest ratings and price target changes.

21/11/2017 Broker: Oppenheimer Rating: Hold Downgrade
13/11/2017 Broker: UBS Rating: Hold New Target: $24.0 Downgrade
08/11/2017 Broker: Canaccord Genuity Rating: Hold Old Target: $38 New Target: $24 Maintain
08/11/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $40 New Target: $27 Maintain
08/11/2017 Broker: Goldman Sachs Old Rating: Buy New Rating: Neutral Old Target: $55 Downgrade
08/11/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
08/11/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $70 New Target: $50 Maintain
08/11/2017 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
07/11/2017 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Old Target: $56 Downgrade
23/10/2017 Broker: Mizuho Rating: Hold Maintain

The stock 0.02% or $0 on November 22, reaching $21.37. It is down 30.39% since November 23, 2016 and is downtrending. It has underperformed by 47.09% the S&P500.

Mallinckrodt public limited company develops, makes, markets and distributes branded and generic specialty pharmaceutical products and therapies. The company has market cap of $2.03 billion. The Firm focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. It currently has negative earnings. The Company’s divisions include Specialty Brands and Specialty Generics.

More notable recent Mallinckrodt PLC (NYSE:MNK) news were published by: Seekingalpha.com which released: “Mallinckrodt: Where Does It Go From Here?” on November 09, 2017, also Prnewswire.com with their article: “Mallinckrodt plc Reports Earnings Results for Third Quarter of Fiscal 2017” published on November 07, 2017, Nasdaq.com published: “Earnings Reaction History: Mallinckrodt plc, 45.5% Follow-Through Indicator, 5 …” on November 07, 2017. More interesting news about Mallinckrodt PLC (NYSE:MNK) were released by: Streetinsider.com and their article: “Oppenheimer Downgrades Mallinckrodt plc (MNK) to Perform” published on November 22, 2017 as well as Prnewswire.com‘s news article titled: “Mallinckrodt plc Presents Health Economic Data on OFIRMEV® (acetaminophen …” with publication date: November 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: